AdvanSix Inc. (ASIX)
NYSE: ASIX
· Real-Time Price · USD
24.21
-0.06 (-0.25%)
At close: Jun 17, 2025, 11:48 AM
AdvanSix Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Caprolactam Revenue | 276.3M | 298.38M | 319.86M | 316.13M |
| Caprolactam Revenue Growth | -7.40% | -6.72% | +1.18% | n/a |
| Chemical Intermediates Revenue | 434.6M | 437.68M | 511.51M | 544.5M |
| Chemical Intermediates Revenue Growth | -0.70% | -14.44% | -6.06% | n/a |
| Nylon Resins Revenue | 348.5M | 356.63M | 485.24M | 422.9M |
| Nylon Resins Revenue Growth | -2.28% | -26.50% | +14.74% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 212.59M | 283.5M | 323.1M | 302.12M | 267M | 240M | 244M | 1.19M |
| Non-Us Revenue Growth | -25.02% | -12.26% | +6.94% | +13.16% | +11.25% | -1.64% | +20421.45% | n/a |
| United States Revenue | 1.3B | 1.25B | 1.62B | 1.38B | 891M | 1.06B | 1.27B | n/a |
| United States Revenue Growth | +4.39% | -22.95% | +17.36% | +55.16% | -15.70% | -16.84% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 23.41M | 21.73M | 24.27M | 24.43M | 23.59M | 24.83M | 21.59M | 24.01M | 25.11M | 22.63M | 23.07M | 20.84M | 21.21M | 20.87M | 21.12M | 21.68M | 19.31M | 20.04M | 16.18M | 17.91M | 16.74M | 16.69M | 19.26M | 20.01M | 19.41M | 26.04M | 18.06M | 17.92M | 19.21M | 18.79M | 19.09M | 18.13M | 16.81M | 19.8M | 11.7M | 10.88M | 11.38M | 13.19M | 14.61M | 13.21M | 11.39M |
| Selling, General, and Administrative Revenue Growth | +7.71% | -10.43% | -0.68% | +3.55% | -4.97% | +15.02% | -10.10% | -4.39% | +10.99% | -1.91% | +10.69% | -1.74% | +1.61% | -1.17% | -2.59% | +12.30% | -3.66% | +23.89% | -9.68% | +7.00% | +0.29% | -13.34% | -3.74% | +3.07% | -25.43% | +44.18% | +0.77% | -6.74% | +2.24% | -1.54% | +5.27% | +7.88% | -15.14% | +69.34% | +7.53% | -4.42% | -13.76% | -9.69% | +10.61% | +15.99% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | 9.8M | n/a | n/a | n/a | 12.5M | n/a | n/a | n/a | 14M | n/a | n/a | n/a | 11.8M | n/a | n/a | n/a | 13.9M | n/a | n/a | n/a | 14.8M | n/a | n/a | n/a | 12.9M | n/a | n/a | n/a | 13.76M | n/a | n/a | n/a | 12.81M | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a |